EP1802205A1 - Produit a base de jaune d'oeuf liquide comprenant une lysophospholipoproteine - Google Patents

Produit a base de jaune d'oeuf liquide comprenant une lysophospholipoproteine

Info

Publication number
EP1802205A1
EP1802205A1 EP04727797A EP04727797A EP1802205A1 EP 1802205 A1 EP1802205 A1 EP 1802205A1 EP 04727797 A EP04727797 A EP 04727797A EP 04727797 A EP04727797 A EP 04727797A EP 1802205 A1 EP1802205 A1 EP 1802205A1
Authority
EP
European Patent Office
Prior art keywords
product
prepared according
product prepared
egg yolk
liquid egg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04727797A
Other languages
German (de)
English (en)
Inventor
James S. Campbell
Derk W. Te Bokkel
Kristen D. Thatcher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inovatech Egg Products
Original Assignee
Inovatech Egg Products
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovatech Egg Products filed Critical Inovatech Egg Products
Publication of EP1802205A1 publication Critical patent/EP1802205A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L15/00—Egg products; Preparation or treatment thereof
    • A23L15/30—Addition of substances other than those covered by A23L15/20 – A23L15/25
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L15/00—Egg products; Preparation or treatment thereof
    • A23L15/25—Addition or treatment with microorganisms or enzymes

Definitions

  • This invention pertains to a novel liquid egg yolk product which contains lysophospholipoprotein. More particularly, this invention pertains to a novel liquid egg yolk product containing lysophospholipoprotein from a phospholipoprotein modified using a non-animal derived phosphohpase A, and a process therefor, which is kosher, does not have a porcine or bovine source, and does not contain appreciable levels of amylase.
  • the product is useful as an emulsifier in foodstuffs such as sauces, spreads, mayonnaise, dressings, salad dressings, and the like.
  • Phospholipases are enzymes which act on phospholipids which are found in animal and vegetable cells. Phospholipases are selective enzymes which are classified according to their site of action in the phospholipid molecule. Thus, a phosphohpase Al hydrolyzes the bond between the fatty acid and the glycerine residue at the 1-position of the phospholipid.
  • lysophospholipid The hydrolysis of a phospholipid by a phosphohpase results in the production of a "lysophospholipid".
  • phospholipids have many industrial uses, lysophospholipids have been shown to be particularly suitable for certain industrial applications. Lysophospholipids have a high solubility in water and this property gives them enhanced emulsification properties in oil/ water emulsions. Lysophospholipids have an ability to form emulsions which are reasonably stable to changing pH conditions, including acid conditions, and they are resistant to changing temperatures. The ability of the lysophospholipid to form an oil-water or water- oil emulsion is not reduced by the presence of ions, such as magnesium or calcium ions.
  • lysophospholipids make them particularly desirable for use in the food, cosmetics and pharmaceutical industries. It has been demon- strated that the conversion of a phospholipid to a lysophospholipid in a phospholipid containing substance, such as a food product, generally leads to an improvement in the stability of that substance.
  • the most commonly used phosphohpase in the industrial hydrolysis of phospholipids is pancreatin, which is an enzyme prepared from the pancreas of pigs. Enzymatic hydrolysis of a phospholipid, using a phosphohpase isolated from a micro-organism is, however, known. Such hydrolysis using a phosphohpase A is described, for example, in Japanese Unexamined Patent Publication No.
  • pancreatin has better properties than enzymes isolated from microorganisms
  • hydrolysis of a phospholipid using pancreatin has many disadvantages. Firstly, it may be necessary to make continual adjustments to the pH of the reaction mixture during hydrolysis of a phospholipid substrate with porcine pancreatin.
  • the optimum pH for activity of pancreatin is in the range from neutral to weakly alkaline.
  • the release of free fatty acids causes the pH to drop, that is, it increases the acidity of the reaction mixture, so that unless counter action is taken, the mixture will become acidic, and therefore outside the pH range for optimum activity of the enzyme.
  • porcine pancreatin has another disadvantage because it is not fully deactivated by heat treatment, and even treatment of the enzyme at a temperature of 95 °C for 30 minutes may not sufficiently deactivate the residual enzyme.
  • the use of a higher temperature is impossible in view of the sensitivity of the phospholipid and free fatty acids to heat.
  • the phosphohpase A is also active when the phospholipid is complexed with protein. After the treatment with the phosphohpase, the lysophospholipoprotein is formed. The lysophospholipid is complexed with a protein.
  • the lysophospholipoprotein containing material disclosed in GB-B-1, 525, 929 has achieved considerable commercial success as an emulsion stabilizer, particularly in oil-in- water emulsions. They enabled the manufacture of sterilizable emulsions, which in practice turned out to be commercially very successful, because they had a long shelf life and an excellent creamy taste.
  • Japanese Abstract No. 58212783 A2 discloses a process whereby a microorganism, e.g. Streptomyces scabies ATCC15485 or Streptomyces achromogenes variety streptozoticus NRRL2697, belonging to the genus Streptomyces, and having the ability to produce phosphohpase A, is cultivated in a culture medium at 22° C to 40° C and a neutral or slightly alkaline pH for about 2 to 6 days. The phosphohpase A is collected mainly from the culture fluid.
  • Japanese Abstract No. 06153939 A2, Snow Brand Milk Prod. Co. Ltd. discloses a process whereby an alga of the genus Euglena (preferably Euglena gracilis) having the ability to produce phosphohpase A is cultured in a culture medium containing a carbon source (preferably glucose), a nitrogen source (preferably glutamic acid or diammonium hydrogenphosphate) at 4-35 ratio (C/N) under conditions of preferably pH 3.0-4.5, 20-32 °C culture temperature and irradiation with light or in the dark for 3-7 days, to produce and accumulate phosphohpase A in the organism. The resultant phosphohpase A is then separated and collected to provide the objective phosphohpase A.
  • a carbon source preferably glucose
  • a nitrogen source preferably glutamic acid or diammonium hydrogenphosphate
  • U.S. Patent No. 5,521,080 Hattori et al. discloses a method for preparing a phosphohpase Al which comprises (a) culturing a phosphohpase Al producing strain of Aspergillus under conditions which allow for the production of the phosphohpase Al; (b) after culturing, diluting the culture with water or an appropri- ate buffer solution; (c) filtering the resulting solution under pressure to remove any insoluble matter; and optionally (d) purifying the enzyme.
  • U.S. Patent Nos. 5,378,623 and 5,538,874, Hattori et al. are related and disclose a phosphohpase Al which is capable of hydrolyzing a phospholipid to produce a 2- acyl lysophospholipid and is obtainable from species of the fungus Aspergillus.
  • EP 0 575 133 Bl discloses a phosphohpase Al obtainable from fungus selected from Aspergillus niger and Aspergillus oryzae character- ized in that said phosphohpase Al: (a) hydrolyzes phospholipid between about pH 2.5 and about pH 6.0; (b) has a molecular weight of between about 30,000 and about 40,000 daltons, as determined by sodium dodecyl sulphate polyacrylamide gel electrophoresis; (c) has a stability to temperature with an upper limit of between about 45 and about 90°C; (d) has a pi under isoelectric point electrophoresis at about pH 2.8 to about pH 4.5; and (e) has an optimum temperature for activity of from about 30 to about 65 °C.
  • U.S. Patent No. 5,028,447, Schenk discloses a process whereby oil and water emulsions which contain a phosphohpoprotein material which has been modified by phosphohpase A, and at least one native starch based thickening agent, are prepared by subsequently gelatinizing the thickening agent, incorporating the modified phosphohpoprotein containing material into the gelatinized thickening agent, then incorporating the oil (which may at least partially be replaced by a low-calorie fat substitute) and finally homogenizing the mixture obtained.
  • Canadian Patent No. 1,210,224 is related.
  • EP 0 319 064 Bl discloses a process for the preparation of a water and oil emulsion comprising a phosphohpoprotein containing material, which has been modified by phosphohpase A, and at least one native starch based thickening agent, which comprises: (a) at least partly gelatinizing the native starch based thickening agent; (b) incorporating the phosphohpoprotein containing material, which has been modified by phosphohpase A, into the gelatinized native starch based thickening agent; (c) incorporating from 5% to 85% by weight of oil or fat containing oil into the mixture obtained in step (b); and (d) homogenizing the final mixture obtained.
  • U.K. Patent No. 1,585, 105, Unilever Limited discloses an oil-in-water emulsion which contains a phosphohpase A-treated phosphohpoprotein having a degree of conversion of at least 55 % and at least one thickening agent in a proportion which is less than that required for obtaining an emulsion of the same composition and viscosity but containing phosphohpoprotein of a lower degree of conversion.
  • U.S. Patent No. 5,082,674 and Canadian Patent No. 2,026,447, Carrell et al. disclose a process for the manufacture of a lysophospholipoprotein-comprising foodstuff.
  • the dried lysophospholipoprotein or dried lysophospholipoprotein- comprising material preferably having a moisture content of at most 10 wt% . , at a level of 0.1-90 wt. % therein, is used as a texture-modifying agent, a glossing agent, a freeze-fhaw stabilizing agent, a heat-stabilizing agent and a syneresis-inhibiting agent.
  • U.S. Patent No. 5,314,706, Colarow et al. discloses an egg yolk fortified with exogenous soybean lysophosphatidylcholine contained in exogenous soybean lysophospholipids which is employed as an emulsification agent in oil and water emulsions, particularly in emulsions which are sterilized.
  • the agent may be obtained by hydrolyzing phospholipids derived from soybeans with phosphohpase A2, deactivating the phosphohpase A2 with a proteolytic enzyme and then inactivating the proteolytic enzyme by heat-treatment at a temperature of from 80° C to 90° C.
  • Egg yolk is fortified by combining and homogenizing the so-obtained lysophospholipids, or exogenous phospholipids containing lysophosphatidylcholine.
  • U.S. Patent No. 5,750,164, Saito et al. discloses a method of decreasing cholesterol concentration in eggs, processed egg foodstuffs, meat, fish meat, dairy products and processed foodstuffs thereof, which includes hydrolyzing phospholipids in the eggs or processed egg foodstuffs or other products with one member selected from the group of phosphohpase A,, A 2 , B, D, lysophospholipase and a mixture thereof, and subjecting the phospholipid-hydrolyzed eggs or processed egg foodstuffs or other products to a conventional cholesterol-decreasing treatment.
  • Japanese patent Abstract No. 62262998 A2, QP Corp. discloses a process whereby a natural phospholipid-containing substance such as egg yolk is added with a phosphohpase A2 preparation-containing material) (e.g. purified phosphohpase A2 preparation originated from animal pancreas) to effect enzymatic reaction.
  • the phospholipid in the substance is decomposed by the reaction to obtain a lysophospholipid-containing material.
  • the obtained lysophospholipid-containing material is dried at about ⁇ 80 °C by spray drying, etc. , to powder having a water content of ⁇ 10% .
  • the powder is extracted with a polar solvent such as ethanol to extract lysophospholipid.
  • the solvent is distilled from the extract under reduced pressure to obtain the objective lysophospholipid-containing material composed of 68 wt. % neutral lipid and 32 wt. % phospholipid (30 wt. % thereof is lysophospholipid).
  • Japanese patent Abstract No. 63209742 A2, QP Corp. discloses a method whereby an emulsifier is prepared by mixing phospholipid, protein, phosphohpase A2 and clean water uniformly in a mixer or a colloid mill, etc., treating at ca. 40 °C and drying if necessary.
  • Suitable protein is albumin, globulin, gelatin, etc.
  • suitable proportion of protein to be present in aqueous suspension of phospholipid is l:(ca 0.5 to 2) phospholipid to protein.
  • the phosphohpase A2 is an enzyme for hydrolyzing the fatty acid ester moiety at the middle part of a glyceride constituting the phospholipid, and the amount thereof to be used is ca. 0.1 to 5 wt. % based on the amount of the phospholipid.
  • U.S. Patent No. 5,213,968, Castle et al. discloses a process whereby emulsifying agents are prepared by sequentially treating a biological material with a protease and a lipase.
  • the enzymatically treated biological material may be pasteurized during or following the enzymatic treatment.
  • EP 0 414 024 Bl Societe des Produits Nestle S.A. discloses a process for the preparation of an emulsifying agent which comprises treating a biological material containing a lipid as well as a lipoprotein and/or a protein with a protease and a lipase and pasteurizing the product.
  • the treatment with the protease and the lipase is carried out sequentially in any order.
  • the present invention relates to a process for the manufacture of lysophospholipoprotein-comprising foodstuffs, such as sauces, spreads, mayonnaise, dressings, soups, bakery products, creamers, creamer-thickeners, ice cream, drinks, dairy products, desserts, sherbets, meals, and combinations thereof, with no detectable amylase (and protease) activity.
  • foodstuffs such as sauces, spreads, mayonnaise, dressings, soups, bakery products, creamers, creamer-thickeners, ice cream, drinks, dairy products, desserts, sherbets, meals, and combinations thereof, with no detectable amylase (and protease) activity.
  • the invention is directed to a process for the manufacture of a liquid egg yolk product containing lysophospholipoprotein comprising: (a) processing a phosphohpase A-containing microbial fermentate to remove amylase and protease co-products of the fermentation to produce a refined phosphohpase A-containing microbial product; and (b) combining a liquid egg yolk with the refined phosphohpase A-containing microbial product of step (a) to produce a modified liquid egg yolk product containing lysophospholipoprotein, said modified liquid egg yolk product having (i) a degree of conversion of phosphohpoprotein to lysophospholipoprotein of at least 10%; and (ii) an amylase activity of less than 50 units/litre.
  • the phosphohpase A-containing fermentate of step (a) can be produced by a fermentation of a phosphohpase A-producing microorganism in a nutrient medium.
  • Suitable prior art phosphohpase A producing microorganisms can be used in the invention but a preferred microorganism can be Streptomyces violaceoruber or a genetically modified Thermomyces lanuginous/Fusarium oxysporum.
  • Step (a) can be conducted at a temperature below about 20 °C and at a pH between about 4.9 and 5.2.
  • the undesirable amylase and protease co-products can be removed in step (a) by passing the fermentate through a cross-flow dialysis apparatus having a PES 50K membrane.
  • the liquid egg yolk product containing lysophosphoprotein can have a phosphohpase activity of less than 250 units/litre.
  • the liquid egg yolk product containing lysophospholipoprotein can have a protease activity of less than 0.01 fluorescence units/ml/min.
  • the invention is also directed to a product prepared according to the process of the invention.
  • the product can contain up to 20% added salts, and up to 50% added carbohydrates, including sugar, malto-dextrin, glucose or corn syrup solids.
  • the product can contain up to 75 % added liquid egg albumin or concentrated liquid egg albumin.
  • the product can be spray dried at an inlet temperature of from about 200 °C to about 250°C and an air outlet temperature from about 75 °C to about 100°C so that the final moisture of the dried product is less than about 10% by weight.
  • the product can be incorporated into an emulsion of oil, water, vinegar, starch, sugar and salt.
  • the emulsion can also include egg yolk.
  • Figure 1 illustrates a schematic flow sheet of a process for modifying liquid egg yolk with refined phosphohpase A to produce a modified egg yolk product contain- ing lysophospholipoprotein.
  • Figure 2 illustrates a plot of the amount of phosphohpase A passing in the permeate and amylase concentrating in the retentate after passing a phosphohpase A and amylase fermentator through a dialysis filter having a PES 50K membrane.
  • Figure 3 illustrates a plot of effect of mayonnaise pH on mayonnaise viscosity.
  • Figure 4 illustrates a plot of the effect of enzyme modified yolk pH on mayonnaise viscosity.
  • Figure 5 illustrates a combination of Figures 3 and 4 and represents a plot of the effect of enzyme modified yolk pH on mayonnaise pH.
  • Figure 6 illustrates a plot of volume over time of soda ash added to yolk to maintain constant pH at different temperatures.
  • Figure 7 illustrates a plot of hydrolysis of starch samples after different incubation times with porcine pancreatic 2-amylase.
  • Figure 8 illustrates a plot of time course of saccharide formation of A. pullulans amylase preparation from maltodextrin DE.
  • FIGs 9 A and 9B illustrates plots of time course of glucose production of A. pullulans amylase preparation from maltodextrin (A) and cornstarch (B).
  • Figure 10 illustrates plots of production of soluble carbohydrate in white bread with Aspergillus intermediate temperature stability enzyme.
  • Figure 11 illustrates a plot of the relationship between the rate of starch viscosity decrease with honey.
  • Figure 12 illustrates a plot of the effect of pH on honey amylase catalyzed degrada- tion of unmodified waxy maize starch at different pH values.
  • the emulsions prepared according to the invention can have either the oil phase or the aqueous phase as the continuous phase, and are in this specification referred to as water-in-oil emulsions and oil-in- water emulsions, respectively.
  • Oil-in- water emulsions are preferred.
  • the latter type of emulsion means for the purpose of this specification continuous aqueous phases containing any amount of fat and/or oil in dispersed form.
  • Examples of emulsions which come under this definition are edible products like phase inversion margarines, soups or sauces, natural or artificial fruit juices, mayonnaise, dressings or spreads.
  • phospholipoprotein-containing substances examples include casein, skim milk, buttermilk, whey, cream, soyabean, yeast, egg yolk, whole egg, blood serum and wheat proteins.
  • Egg yolk is used preferably as source of the phosphohpoprotein.
  • Egg yolk or other sources of phosphohpoprotein can be subjected to the action of phosphohpase A and the modified product is then incorporated in the products according to the invention.
  • the inventors herein have invented a novel liquid amylase-free egg yolk product containing lysophospholipoprotein, which is not derived from animal sources, notably porcine or bovine sources.
  • the inventors have also invented a process for manufacturing a liquid egg yolk product containing lysophospholipoprotein.
  • the inventors have prepared a process for the manufacture of a liquid egg yolk product comprising lysophospholipoprotein which comprises: (a) processing a fermentation of a microorganism in a nutrient medium which produces microbial phosphohpase A to remove undesirable amylase and protease co-products of the fermentation to produce a refined microbial phosphohpase A product; and (b) modifying a liquid egg yolk with the refined microbial phosphohpase A to produce a modified liquid egg yolk product which contains lysophospholipoprotein, the modified liquid egg yolk product comprising lysophospholipoprotein having a degree of conversion of phosphohpoprotein to lysophospholipoprotein of at least 10% and an amylase activity of less than 50 units per litre.
  • the process produces a modified liquid egg yolk product containing lysophospholipoprotein which has a degree of conversion of phosphohpoprotein to lysophospholipoprotein of at least 50 % .
  • a problem with most methods of producing phosphohpase A by microbial fermentation is that high levels of amylase are obtained as a by-product. Protease is also produced as a byproduct. High levels of amylase are undesirable because the amylase breaks down starch into undesirable products. Many food products are starch-based and hence significant levels of amylase in a food additive cannot be tolerated because the amylase leads to breakdown of the starch base. Significant protease levels are also to be discouraged since the protease tends to react with egg white and other proteins and cause water in the oil-water emulsions to begin to separate.
  • the inventors have discovered a method and processing equipment which enables the amylase to be separated from the microorganism produced phosphohpase A fermentation medium so that the amylase activity in the end product is basically non-existent. Amylase activities of less than 50 units per litre have been obtained.
  • the system according to the invention uses a specific dialysis procedure for separating the amylase and the protease from the crude phosphohpase A medium.
  • the inventors have tested and rejected a large number of different dialysis machines in an effort to discover a feasible method for separating amylase from the crude phosphohpase A fermentation medium. None were found to be satisfactory for purposes of the invention.
  • the inventors have now found a dialysis system available from North Carolina SRT under the model number NCSRT UF with a PES 50K membrane, or smaller, capable of separating the amylase and protease from the phosphohpase A.
  • a suitable microbial fermentation product containing phosphohpase A is available from Genencor.
  • One type of phosphohpase A microorganism fermentation product that can be used in the process according to the invention is a Streptomyces viola ceoruber derived product available from Genencor.
  • Another microorganism that can be used in the process is a genetically modified thermomyces lanuginousl Fusarium oxysporum produced by submerged fermentation and available from Novozymes.
  • Other suitable microbial phospholipase A products may be suitable for purposes of the invention, including one or more of the phosphohpase A-containing products referred to in the Background.
  • the key to the subject invention is that the inventors have discovered a method and apparatus for reducing the amylase and protease concentrations of the crude microbial enzyme products available from commercial sources so that the amylase and protease activity are reduced to insignificant levels.
  • the crude enzyme solution should be prefiltered through a 5 micron or less filter.
  • kosher sodium citrate kosher citric acid
  • crude enzyme obtained from Genencor approx. 100 lbs. (45L)
  • RO purified water The following equipment is used: an NCSRT UF system with PES 50K membrane module for dialysis stage. Any other type of suitable tangential flow or spiral wound membrane system with a similar membrane type can be used.
  • Method of Preparation (1) Prepare approximately 2 to 6 volumes of citrate buffer at pH 4.8 to 5.2. (2) Load the crude enzyme into feed tank. Collect a sample from the tank for testing. (3) Start the dialysis system by setting flow rates so that the flux (litres/m 2 /hour) is approximately 2 to 10 LMH and adjust the back pressure valve to between 0 to 20 psi on the retentate exit line of the membrane. Collect the permeate in pail(s) or a suitable receiver tank (150 to 200L). The permeate line flows should not be blocked or build up significant back pressure. (4) Start the citrate buffer flow and set it to match the permeate flow into the feed tank.
  • Stage Two A stage two procedure is used to concentrate the product, when required.
  • the following ingredients are used: 150 to 200L of collected PA2 Permeate from Stage One; and RO purified water.
  • the following equipment is required: NCSRT UF system with a 10K or 5K membrane module for the concentration stage (or other suitable tangential flow or spiral wound membrane systems).
  • Method of Preparation (1) Provide sufficient cooling to the unit to keep the enzyme in the feed tank below 20°C, preferably at 10°C, if possible. (2) Load the dialysed enzyme (PA2 Permeate from Stage One) into the feed tank. Collect a sample from the tank for analysis. (3) Start the concentration system by setting flow rates (cross flow of 20 to 100 L/min.) so that the flux is in the range of 5 to 60 LMH and adjust the back pressure valve to generate between 10 to 100 psi on the retentate exit line of the membrane. (4) Reduce the volume in the feed tank to approximately 10 to 20 L (or less if care is taken to prevent air entrainment and turbulence). This will take approximately 5 to 20 hours to complete. (5) Shut the system down and collect the remaining material from the system and feed tank.
  • Figure 2 illustrates a plot of the amount of phosphohpase A passing in the permeate and amylase concentrating in the retentate after passing a phosphohpase A and amylase fermentator through a dialysis filter having a PES 50K membrane.
  • Standard Operating Procedure for Producing Modified Liquid Egg Yolk Products Containing Lysophospholipoprotein from Refined Amylase and Protease-Free enzyme Product Obtained from the Stage One Dialysis or the Stage Two Concentration (1) Prepare liquid salt yolk in churn. (2) Prepare alkaline base solution. (3) Adjust batch initial pH. (4) Adjust yolk temperature. (5) Add enzyme. (6) Perform hydrolysis step and add alkaline base as necessary. (7) Terminate hydrolysis. (8) Pasteurize. (9) Package.
  • Figure 1 illustrates a schematic flow sheet of a process for modifying liquid egg yolk with refined phosphohpase A to produce a modified egg yolk product containing lysophospholipoprotein.
  • Figure 6 illustrates a plot of volume over time of soda ash added to yolk to maintain constant pH at different temperatures.
  • Figure 3 illustrates a plot of effect of mayonnaise pH on mayonnaise viscosity.
  • Figure 4 illustrates a plot of the effect of enzyme modified yolk pH on mayonnaise viscosity.
  • Figure 5 illustrates a combination of Figures 3 and 4 and represents a plot of the effect of yolk pH on mayonnaise pH.
  • Figure 7 illustrates a plot of hydrolysis of starch samples after different incubation times with porcine pancreatic 2-amylase.
  • Figure 8 illustrates a plot of time course of saccharide formation of A. pullulans amylase preparation from maltodextrin DE.
  • Figures 9A and 9B illustrate plots of time course of glucose production of A. pullulans amylase preparation from maltodextrin (A) and cornstarch (B).
  • Figure 10 illustrates plots of production of soluble carbohydrate in white bread with Aspergillus intermediate temperature stability enzyme.
  • Figure 11 illustrates a plot of the relationship between the rate of starch viscosity decrease with honey.
  • Figure 12 illustrates a plot of the effect of pH on honey amylase catalyzed degradation of unmodified waxy maize starch at different pH values.
  • the following table illustrates a recipe for a typical mayonnaise incorporating the liquid egg yolk product according to the invention.
  • Reagents (1) 0.02 M sodium phosphate buffer, pH 6.9 containing 0.006 M sodium chloride. (2) 2.0 M sodium hydroxide. (3) Dinitrosalicylic acid color reragent. Dissolve l.Og 3,5- dinitrosalicylic acid in 20ml 2M NaOH. Add slowly 30. Og sodium potassium tartrate tetrahydrate. Dilute to a final volume of 100ml with distilled water. Store in a tightly sealed container and protect from CO 2 . Stable for 2 weeks. (4) 1 % starch. Dissolve l.Og of soluble starch in 100ml 0.02M sodium phosphate buffer, pH 6.9, containing 0.006M NaCl. Bring to a gentle boil to dissolve.
  • Egg Samples (1) Measure 0.500g of liquid egg yolk (or 0.250g dried egg yolk, 0.500g liquid egg white, 0.1 OOg dried egg white) into a 1.5ml Eppendorf tube. (2) Bring to l.OOg with NaP buffer (prepared above). (3) Vortex mixture until the egg and buffer are sufficiently mixed. (4) Prepare dilutions of this mixture in 1.5ml Eppendorf tubes. Dilute 2x, lOx, 20x and 50x. (5) Centrifuge all tubes at 10,000rpm for 20 minutes. Do not resuspend. Supernatant will be used as sample.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Seasonings (AREA)

Abstract

L'invention concerne un nouveau produit à base de jaune d'oeuf liquide contenant une lysophospholipoprotéine. Plus particulièrement, l'invention concerne un nouveau produit à base de jaune d'oeuf liquide contenant une lysophospholipoprotéine provenant d'une phospholipoprotéine modifiée au moyen d'une phospholipase A dérivée non animale, ainsi qu'un procédé associé. Ce produit, qui est casher, n'est pas d'origine porcine ou bovine et présente une très faible teneur en amylase. Ledit produit est utile comme émulsifiant dans des produits alimentaires tels que des sauces, des pâtes à tartiner, de la mayonnaise, des assaisonnements, des sauces à salade et analogues. Un procédé de fabrication d'un produit à base de jaune d'oeuf liquide contenant une lysophospholipoprotéine consiste (a) à traiter un fermentat microbien contenant une phospholipase A de manière à enlever l'amylase indésirable et les sous-produits de protéase de la fermentation en vue de la production d'un produit microbien contenant une phospholipase A raffiné, et (b) à modifier un jaune d'oeuf liquide au moyen du produit microbien contenant une phospholipase A raffiné de l'étape (a) en vue de la production d'un produit à base de jaune d'oeuf liquide modifié contenant une lysophospholipoprotéine, ledit produit à base de jaune d'oeuf liquide modifié présentant (i) un degré de conversion phospholipoprotéine-lysophospholipoprotéine d'au moins 10 %, et (ii) une activité amylase inférieure à 50 unités/litre.
EP04727797A 2004-04-16 2004-04-16 Produit a base de jaune d'oeuf liquide comprenant une lysophospholipoproteine Withdrawn EP1802205A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2004/000572 WO2005099487A1 (fr) 2004-04-16 2004-04-16 Produit a base de jaune d'oeuf liquide comprenant une lysophospholipoproteine

Publications (1)

Publication Number Publication Date
EP1802205A1 true EP1802205A1 (fr) 2007-07-04

Family

ID=34957277

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04727797A Withdrawn EP1802205A1 (fr) 2004-04-16 2004-04-16 Produit a base de jaune d'oeuf liquide comprenant une lysophospholipoproteine

Country Status (3)

Country Link
EP (1) EP1802205A1 (fr)
CA (1) CA2587488A1 (fr)
WO (1) WO2005099487A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008090A (es) 2007-02-01 2009-08-12 Dsm Ip Assets Bv Metodo para producir tarta con fosfolipasa a.
US20090246319A1 (en) * 2008-03-31 2009-10-01 Kraft Foods Holdings, Inc. Process And Formulation For Making An Egg Product With Increased Functionality And Flavor
US8916156B2 (en) 2010-07-02 2014-12-23 Rembrandt Enterprises, Inc. Isolated egg protein and egg lipid materials, and methods for producing the same
US8642038B2 (en) 2010-07-02 2014-02-04 Rembrandt Enterprises, Inc. Isolated egg protein and egg lipid materials, and methods for producing the same
MX2013015183A (es) * 2011-06-20 2014-03-31 Nestec Sa Emulsion que comprende lisofosfolipidos.
EP3644761A4 (fr) 2017-06-26 2021-03-24 Michael Foods, Inc. Fractionnement de jaune d' oeuf

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1525929A (en) * 1974-11-25 1978-09-27 Unilever Ltd Stabilised emulsions comprising phospholipoprotein
GB1585105A (en) * 1976-04-29 1981-02-25 Unilever Ltd Emulsions
DE3423699C1 (de) * 1984-06-27 1986-01-16 Maggi AG, Kempttal Saucenverbesserer in Tuben
EP0319064B1 (fr) * 1987-12-03 1992-05-13 Unilever N.V. Procédé de préparation d'une émulsion eau dans huile
ATE97555T1 (de) * 1989-09-29 1993-12-15 Unilever Nv Getrocknetes lyso-phospholipoprotein enthaltendes nahrungsmittel.
CA2213468C (fr) * 1995-02-22 2006-04-11 Unilever Plc Sauce pouvant cuire a haute temperature
JP3464560B2 (ja) * 1995-04-14 2003-11-10 旭電化工業株式会社 水中油型乳化脂及びその製造法
JP3589904B2 (ja) * 1999-06-17 2004-11-17 花王株式会社 酸性水中油型乳化組成物
US6863908B2 (en) * 2002-04-25 2005-03-08 Unilever Bestfoods, North America Division Of Conopco Inc. Universal sauce base
US6773731B2 (en) * 2002-10-18 2004-08-10 James S. Campbell Liquid egg yolk product comprising lysophospholipoprotein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005099487A1 *

Also Published As

Publication number Publication date
CA2587488A1 (fr) 2005-10-27
WO2005099487A1 (fr) 2005-10-27

Similar Documents

Publication Publication Date Title
US6773731B2 (en) Liquid egg yolk product comprising lysophospholipoprotein
JP3466189B2 (ja) 米ぬかの安定化方法及び米ぬか生成物
RU2233599C2 (ru) СПОСОБ ПОЛУЧЕНИЯ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ ВОДОРАСТВОРИМЫЙ β-ГЛЮКАН, (ВАРИАНТЫ) И ИЗГОТАВЛИВАЕМЫЕ ИЗ НЕЕ ПРОДУКТЫ
RU2185075C2 (ru) Способ получения съедобного гидролизата (варианты)
US20200123494A1 (en) Method for obtaining protein from whey or molasses
WO2005099487A1 (fr) Produit a base de jaune d'oeuf liquide comprenant une lysophospholipoproteine
US7897186B2 (en) Modified whey protein compositions having improved foaming properties
EP0414024B2 (fr) Procédé de préparation d'un émulsionnant
RU2428047C1 (ru) Способ получения гидролизата сывороточных белков с высокой степенью гидролиза и гидролизат сывороточных белков с высокой степенью гидролиза
AU2002336717A1 (en) Modified whey protein compositions having improved foaming properties
BRPI0710694A2 (pt) métodos para extrair um ou mais componentes de levedura e para produzir um extrato de levedura, e, uso de uma fosfolipase purificada
JP5447372B2 (ja) 脱脂豆乳ペプチドの製造方法
Jayasree Joshi et al. Value Addition and Sustainable Management of Dairy Industry Byproducts
CN112544716A (zh) 一种含植物甾醇酯和燕麦的乳制品及其制备方法
Dhingra et al. Enzymes in Food Industry and Their Regulatory Oversight
JP2020068668A (ja) 乳蛋白質加水分解物及びその製造方法
JP3227893B2 (ja) 調味料およびその製造法
Joshi Value Addition and Sustainable Management of Dairy Industry Byproducts T. Jayasree Joshi, V. Harsha, P. Nandagopal, Asha Ashok, and Sabitra Pokhrel
JP3274646B2 (ja) 乳化性組成物
JP3318048B2 (ja) 蛋白質水溶液の処理方法
JPH0117655B2 (fr)
RU2108381C1 (ru) Основа питательной среды для культивирования микроорганизмов
JP2006081446A (ja) 酵母増殖の促進方法
UA125450C2 (uk) Спосіб виготовлення гідролізату білків молочної сироватки
WO2024159022A2 (fr) Compositions de protéines purifiées et leurs méthodes de production

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070405

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: TE BOKKEL, DERK, W.

Inventor name: CAMPBELL, JAMES, S.

Inventor name: THATCHER, KRISTEN, D.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20120402